Extended Data Fig. 8: TCR^A2-2 and TCR^A24 T cells persist in peripheral blood and upregulate exhaustion markers to similar levels as control TCR-T cells in vivo.

a, Gating strategy to identify percentage and numbers of hCD45⁺ cells, hCD8⁺ T cells, and exhaustion markers on mTCRβ⁺ T cells in mouse peripheral blood. The gates for mTCRβ⁺ cells were set based on mock transduced T cells and the gates for exhaustion markers were set based on fluorescent minus one (FMO) staining. b–f, Percentage of (b) mTCRβ⁺ cells among hCD8⁺ T cells, and percentage of (c) PD-1⁺, (d) TIGIT⁺, (e) TIM-3⁺ or (f) CTLA-4⁺ cells among mTCRβ⁺ cells in mouse PB at indicated days after T cell injection. (b–f) Each dot represents one individual mouse. A threshold of n = 30 hCD3⁺, hCD8⁺, mTCRβ⁺cells detected in the blood was set as a criterion for sample inclusion for analysis. Data shown are from one experiment. g–j, Plots showing percentages of hCD45⁺ among all cells in mouse PB at indicated days after T cell injection, in mice treated with (g) mock, (h) TCR^1G4, (i) TCR^A24, or (j) TCR^A2-2 transduced T cells. Mice in g, i, j, with hCD45⁺ cell frequencies exceeding 20% of total blood cells (indicated by the dotted line) were euthanized due to symptoms of GvHD (Mock #5, TCR^A24 #4, TCR^A2-2 #6). IL-2 injections were reduced on day 24 and fully stopped on day 34. (g–j) Dots represent individual mice, and data shown are from n = 1 experiment.

Source data